Table 1

Baseline characteristics and medication of SLE patients (n = 34) and healthy controls (HC, n = 18) included in the study.

SLE patients

HC

P-value


Total number

34

18

Women/men

28/6

15/3

ns

Age (years, mean ± SD)

41 ± 14

35 ± 11

ns

SLEDAI (median (range))

4 (0 to 17)

C3, g/l (median, range)

0.82 (0.37 to 1.45)

C4, g/l (median, range)

0.21 (0.04 to 0.30)

Anti-dsDNA, E/ml (median, range)

165 (4 to 1,000)

Treatment, n

18

None

4

Glucocorticoids, n

23

median dose (range), dose (mg/day)

5 (3.75 to 60)

Immunosupressive/immunmodulating, n

Hydroxychloroquine

17

median dose (range), users (mg/day)

400 (200 to 600)

Methotrexate

2

median dose (range), users (mg/week)

15 (5 to 25)

Azathioprine

12

median dose (range), users (mg/day)

112.5 (50 to 150)

MMF

4

median dose (range), users (mg/day)

2,500 (1,000 to 3,000)


SLEDAI: systemic lupus erythematosus disease activity index, MMF: mycophenolate mofetil.

Dolff et al. Arthritis Research & Therapy 2011 13:R157   doi:10.1186/ar3474

Open Data